A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Veneer is obtained either by "peeling" the trunk of a tree or by slicing large rectangular blocks of wood known as flitches. The appearance of the grain and figure in wood comes from slicing through the growth rings of a tree and depends upon the angle at which the wood is sliced. There are three main types of veneer-making equipment used commercially:
No human pathogens of comparable virulence have yet emerged from marine species. In 2024 aquaculture production was concentrated in Asia which accounted for around 89% of global aquatic animal aquaculture production, followed by Latin America and the Caribbean (3%), Europe (2%), Africa (2%), Northern America (0.4%) and Oceania (0.2%). The top five countries together produced 82% of the total output; China, Indonesia, India, Viet Nam and Bangladesh. Freshwater systems dominate aquaculture production of aquatic animals, accounting for 64 million tonnes (63%), compared to 38 million tonnes (37%) from marine and coastal systems. Biological control methods to manage parasites are already being used, such as cleaner fish (e.g. lumpsuckers and wrasse) to control sea lice populations in salmon farming. Models are being used to help with spatial planning and siting of fish farms in order to minimize impact.
However, only Lockyer proposed that the line was due to a new element, which he named after the Sun. The formal discovery of the element was made in 1895 by chemists Sir William Ramsay, Per Teodor Cleve, and Nils Abraham Langlet, who found helium emanating from the uranium ore cleveite, which is no longer regarded as a separate mineral species, but as a variety of uraninite. In 1903, large reserves of helium were found in natural gas fields in parts of the United States, by far the largest supplier of the gas. Liquid helium is used in cryogenics (its largest single use, consuming about a quarter of production), and in the cooling of superconducting magnets, with its main commercial application in MRI scanners. Helium's other industrial uses—as a pressurizing and purge gas, as a protective atmosphere for arc welding, and in processes such as growing crystals to make silicon wafers—account for half of the gas produced. A small but well-known use is as a lifting gas in balloons and airships. As with any gas whose density differs from that of air, inhaling a small volume of helium temporarily changes the timbre and quality of the human voice. In scientific research, the behavior of the two fluid phases of helium-4 (helium I and helium II) is important to researchers studying quantum mechanics (in particular the property of superfluidity) and to those looking at the phenomena, such as superconductivity, produced in matter near absolute zero. On Earth, it is relatively rare—5.2 ppm by volume in the atmosphere.
Sources: en.wikipedia.org
== Research data == A comparison of the heart mitochondria in rats (7-year maximum life span) and pigeons (35-year maximum life span) showed that pigeon mitochondria leak fewer free-radicals than rat mitochondria, despite the fact that both animals have similar metabolic rate and cardiac output For mammals there is a direct relationship between mitochondrial membrane fatty acid saturation and maximum life span Studies of the liver lipids of mammals and a bird (pigeon) show an inverse relationship between maximum life span and number of double bonds Selected species of birds and mammals show an inverse relationship between telomere rate of change (shortening) and maximum life span Maximum life span correlates negatively with antioxidant enzyme levels and free-radicals production and positively with rate of DNA repair Female mammals express more Mn−SOD and glutathione peroxidase antioxidant enzymes than males. This has been hypothesized as the reason they live longer. However, mice entirely lacking in glutathione peroxidase 1 do not show a reduction in lifespan.
Symptoms of episcleritis typically include painless redness of the eye (mild pain is possible but atypical), and watery eyes. The pain of episcleritis is typically mild, less severe than in scleritis, and may be tender to palpation. There are two types of episcleritis: the diffuse type, where the redness involves the entire episclera, and the nodular type, where the redness appears more nodular, involving only a small, well-circumscribed area (sectoral). The diffuse type of episcleritis may be less painful than the nodular type. Sometimes, small nodules are present within the episclera, which move slightly over the sclera with gentle pressure. Discharge is absent with episcleritis, and vision is unaffected. Patients with episcleritis experience far less photophobia than patients with uveitis. Episcleritis does not cause the presence of cells or flare in the anterior chamber of the eye. In 80 percent of cases, episcleritis affects only one eye, whereas scleritis often affects both eyes.
The 3D framework [Cu3(btc)2(H2O)3] (btc: benzene-1,3,5-tricarboxylate) (HKUST-1) used in this study was first reported by Williams et al. The open framework of [Cu3(btc)2(H2O)3] is built from dimeric cupric tetracarboxylate units (paddle-wheels) with aqua molecules coordinating to the axial positions and btc bridging ligands. The resulting framework after removal of two water molecules from axial positions possesses porous channel. This activated MOF catalyzes the trimethylcyanosilylation of benzaldehydes with a low conversion (<5% in 24 h) at 293 K. As the reaction temperature was raised to 313 K, a good conversion of 57% with a selectivity of 89% was obtained after 72 h. In comparison, less than 10% conversion was observed for the background reaction (without MOF) under the same conditions. But this strategy suffers from some problems like 1) the decomposition of the framework with increase of the reaction temperature due to the reduction of Cu(II) to Cu(I) by aldehydes; 2) strong solvent inhibition effect; electron donating solvents such as THF competed with aldehydes for coordination to the Cu(II) sites, and no cyanosilylation product was observed in these solvents; 3) the framework instability in some organic solvents. Several other groups have also reported the use of metal centres in MOFs as catalysts. Again, electron-deficient nature of some metals and metal clusters makes the resulting MOFs efficient oxidation catalysts. Mori and coworkers reported MOFs with Cu2 paddle wheel units as heterogeneous catalysts for the oxidation of alcohols.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.